A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer

Abstract

PTEN loss is independently associated with increased risk of lethal progression, particularly in the ERG fusion-negative subgroup. These validated and inexpensive IHC assays may be useful for risk stratification in prostate cancer.